本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Allogene Therapeutics Inc.

1.16
-0.0200-1.69%
盤後1.190.0300+2.59%19:37 EDT
成交量:379.24萬
成交額:450.52萬
市值:2.52億
市盈率:-0.88
高:1.28
開:1.19
低:1.15
收:1.18
資料載入中...
2022/09/21

重要事件披露

8-K - Current report
2022/08/09

重要事件披露

8-K - Current report
2022/08/09

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/07/12

重要事件披露

8-K - Current report
2022/06/17

重要事件披露

8-K - Current report
2022/05/04

重要事件披露

8-K - Current report
2022/05/04

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/04/07

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/02/23

重要事件披露

8-K - Current report
2022/02/23

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/02/23

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/18

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/10/04

持股變動聲明

4 - Statement of changes in beneficial ownership of securities
2021/09/20

持股變動聲明

3 - Initial statement of beneficial ownership of securities
2021/09/17

持股變動聲明

4 - Statement of changes in beneficial ownership of securities